(IPX) IperionX American - Overview
Sector: Basic Materials | Industry: Other Industrial Metals & Mining | Exchange: NASDAQ (USA) | Market Cap: 1.208m USD | Total Return: 64.9% in 12m
Avg Turnover: 8.71M
Warnings
Interest Coverage Ratio -80.2 is critical
Altman Z'' -1.88 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
IperionX Limited (IPX) is a North Carolina-based materials company focused on the domestic supply chain for critical minerals and advanced metal production. The company operates the Titan project in Tennessee, which contains deposits of titanium, zircon, and rare earth elements. Beyond mineral extraction, the firm produces angular and spherical titanium metal powders used in additive manufacturing and high-performance engineering.
The company serves diverse sectors including aerospace, defense, automotive, and medical industries. This integrated business model aims to reduce reliance on foreign supply chains by localized sourcing and processing of titanium, a metal valued for its high strength-to-weight ratio and corrosion resistance. Strategic insights on the company’s long-term valuation can be found on ValueRay.
IperionX transitioned from its previous identity as Hyperion Metals Limited in early 2022 to reflect its expanded focus on sustainable metal technologies. The titanium industry is currently undergoing a shift toward powder metallurgy to reduce material waste and energy consumption compared to traditional Kroll process smelting.
- Titan project mineral resource conversion drives long term titanium and zircon supply
- Commercial scale production of low carbon titanium powder impacts revenue growth
- Aerospace and defense contract wins accelerate adoption of recycled titanium technology
- Domestic supply chain policy and critical mineral subsidies influence capital expenditure
- Strategic partnerships with luxury and electronics brands dictate near term market penetration
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.87 > 0.02 and ΔFCF/TA -75.35 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.17 > 3% & CFO -21.8m > Net Income -105.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.36m) vs 12m ago -87.57% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -80.24 > 6 (EBITDA TTM -110.3m / Interest Expense TTM 1.44m) |
| A: 0.40 (Total Current Assets 69.6m - Total Current Liabilities 17.3m) / Total Assets 129.2m |
| B: -1.11 (Retained Earnings -144.0m / Total Assets 129.2m) |
| C: -0.94 (EBIT TTM -115.2m / Avg Total Assets 122.5m) |
| D: 5.16 (Book Value of Equity 108.2m / Total Liabilities 21.0m) |
| Altman-Z'' = -1.88 = D |
As of May 23, 2026, the stock is trading at USD 36.15 with a total of 201,193 shares traded.
Over the past week, the price has changed by +3.95%,
over one month by +18.90%,
over three months by -12.96% and
over the past year by +64.93%.
IperionX American has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy IPX.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 54.2 | 49.9% |
P/B = 12.9259
Revenue TTM = 0.0 USD
EBIT TTM = -115.2m USD
EBITDA TTM = -110.3m USD
Long Term Debt = 9.39k USD (from longTermDebt, last quarter)
Short Term Debt = 1.11m USD (from shortTermDebt, last quarter)
Debt = 8.19m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.73m
Net Debt = -57.6m USD (calculated: Debt 8.19m - CCE 65.8m)
Enterprise Value = 1.15b USD (1.21b + Debt 8.19m - CCE 65.8m)
Interest Coverage Ratio = -80.24 (Ebit TTM -115.2m / Interest Expense TTM 1.44m)
EV/FCF = -10.26x (Enterprise Value 1.15b / FCF TTM -112.1m)
FCF Yield = -9.74% (FCF TTM -112.1m / Enterprise Value 1.15b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.27m) / Revenue TTM)
Tobins Q-Ratio = 8.91 (Enterprise Value 1.15b / Total Assets 129.2m)
Interest Expense / Debt = 17.52% (Interest Expense 1.44m / Debt 8.19m)
Taxrate = 21.0% (US default 21%)
NOPAT = -91.0m (EBIT -115.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.03 (Total Current Assets 69.6m / Total Current Liabilities 17.3m)
Debt / Equity = 0.08 (Debt 8.19m / totalStockholderEquity, last quarter 108.2m)
Debt / EBITDA = 0.52 (negative EBITDA) (Net Debt -57.6m / EBITDA -110.3m)
Debt / FCF = 0.51 (negative FCF - burning cash) (Net Debt -57.6m / FCF TTM -112.1m)
Total Stockholder Equity = 96.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -86.13% (Net Income -105.5m / Total Assets 129.2m)
RoE = -43.89% (Net Income TTM -105.5m / Total Stockholder Equity 240.4m)
RoCE = -47.92% (EBIT -115.2m / Capital Employed (Equity 240.4m + L.T.Debt 9.39k))
RoIC = -192.9% (out of range, set to none) (NOPAT -91.0m / Invested Capital 47.2m)
WACC = 12.44% (E(1.21b)/V(1.22b) * Re(12.43%) + D(8.19m)/V(1.22b) * Rd(17.52%) * (1-Tc(0.21)))
Discount Rate = 12.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 32.20 | Cagr: -55.68%
[DCF] Fair Price = unknown (Cash Flow -112.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.40 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS next Quarter (2026-09-30): EPS=-0.33 | Chg30d=+0.00% | Revisions=N/A | Analysts=1
EPS current Year (2026-06-30): EPS=-0.98 | Chg30d=+14.72% | Revisions=N/A | GrowthEPS=-720.8% | GrowthRev=+0.0%
EPS next Year (2027-06-30): EPS=-0.49 | Chg30d=-23.75% | Revisions=N/A | GrowthEPS=+49.8% | GrowthRev=+1092.5%